Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-115.

Background: Treatment options for immunotherapy-refractory melanoma are an unmet need. The MASTERKEY-115 phase II, open-label, multicenter trial evaluated talimogene laherparepvec (T-VEC) plus pembrolizumab in advanced melanoma that progressed on prior programmed cell death protein-1 (PD-1) inhibitors.

Methods: Cohorts 1 and 2 comprised patients (unresectable/metastatic melanoma) who had primary or acquired resistance, respectively, and disease progression within 12 weeks of their last anti-PD-1 dose.

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial.

Talimogene laherparepvec (T-VEC) plus ipilimumab has demonstrated greater antitumor activity versus ipilimumab alone, without additional toxicity, in patients with advanced melanoma. Here, we report the 5-year outcomes from a randomized phase II study. These data provide the longest efficacy and safety follow-up for patients with melanoma treated with a combination of an oncolytic virus and a checkpoint inhibitor.

Screening and Optimization of Zinc Removal Potential in Pseudomonas aeruginosa-HMR1 and its Plant Growth-Promoting Attributes.

The soil samples of old Zawar mine sites were sandy texture, basic, electric conductivity range from 16 to 59 dSm with a high content of heavy metals of Zn, Pb, Cd, and Fe, indicating poor soil-health. Two bacterial isolates Pseudomonas aeruginosa HMR1 and P. aeruginosa HMR16 (GenBank-accession-number KJ191700 and KU174205, respectively), differed in the Phylogenetic tree based on 16S-rDNA sequences.